Suarez J I, Sunshine J L, Tarr R, Zaidat O, Selman W R, Kernich C, Landis D M
Department of Neurology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA.
Stroke. 1999 Oct;30(10):2094-100. doi: 10.1161/01.str.30.10.2094.
We sought to evaluate predictors of clinical outcome, angiographic success, and adverse effects after intra-arterial administration of urokinase for acute ischemic stroke.
We designed a Brain Attack program at University Hospitals of Cleveland for diagnosis and treatment of patients presenting within 6 hours of onset of neurological deficit. Patients with ischemia referable to the carotid circulation were treated with intra-arterial urokinase. Angiographic recanalization was assessed at the end of medication infusion. Intracerebral hemorrhage was investigated immediately after and 24 hours after treatment. Stroke severity was determined, followed by long-term outcome.
Fifty-four patients were treated. There was improvement of >/=4 points on the National Institutes of Health Stroke Scale from presentation to 24 hours after onset in 43% of the treated patients, and this was related to the severity of the initial deficit. Forty-eight percent of patients had a Barthel Index score of 95 to 100 at 90 days, and total mortality was 24%. Cranial CT scans revealed intracerebral hemorrhage in 17% of patients in the first 24 hours, and these patients had more severe deficits at presentation. Eighty-seven percent of patients received intravenous heparin after thrombolysis, and 9% of them developed a hemorrhage into infarction. Angiographic recanalization was the rule in complete occlusions of the horizontal portion of the middle cerebral artery, but distal carotid occlusions responded less well to thrombolysis.
The intra-arterial route for thrombolysis allows for greater diagnostic precision and achievement of a higher concentration of the thrombolytic agent in the vicinity of the clot. Disadvantages of this therapy lie in the cost and delay. Severity of stroke and site of angiographic occlusion may be important predictors of successful treatment.
我们旨在评估动脉内给予尿激酶治疗急性缺血性卒中后的临床结局、血管造影成功情况及不良反应的预测因素。
我们在克利夫兰大学医院设计了一个脑卒中介入治疗项目,用于诊断和治疗神经功能缺损发作6小时内就诊的患者。颈内动脉循环缺血的患者接受动脉内尿激酶治疗。在药物输注结束时评估血管造影再通情况。治疗后即刻及24小时后调查颅内出血情况。确定卒中严重程度,随后评估长期结局。
共治疗54例患者。43%的治疗患者从就诊到发病后24小时美国国立卫生研究院卒中量表评分改善≥4分,这与初始缺损的严重程度有关。48%的患者在90天时巴氏指数评分为95至100,总死亡率为24%。头颅CT扫描显示17%的患者在最初24小时内发生颅内出血,这些患者就诊时缺损更严重。87%的患者在溶栓后接受静脉肝素治疗,其中9%发生出血性梗死。血管造影再通在大脑中动脉水平段完全闭塞时较为常见,但颈内动脉远端闭塞对溶栓的反应较差。
动脉内溶栓途径可提高诊断准确性,并在血栓附近达到更高浓度的溶栓剂。该治疗方法的缺点在于费用和延迟。卒中严重程度和血管造影闭塞部位可能是治疗成功的重要预测因素。